Elanco Animal Health Inc. - 10-Q Summary (Q2 2026)
Business Context and Reporting Period
This filing covers the quarterly period ended June 30, 2026. Elanco Animal Health Inc. operates as a single segment global leader in animal health, serving pet and farm animal markets. The company reported strong operational performance driven by new product launches and strategic acquisitions.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Revenue | $1,368 million | $1,241 million | $2,739 million | $2,434 million |
| Gross Profit | $798 million | $713 million | $1,583 million | $1,397 million |
| Gross Margin | 58.3% | 57.5% | 57.8% | 57.4% |
| Net Income | $54 million | $11 million | $111 million | $78 million |
| Diluted EPS | $0.11 | $0.02 | $0.22 | $0.16 |
| Operating Cash Flow (YTD) | $290 million (vs. $233 million YTD 2025) | |||
| Total Debt (Long-term + Current) | $3,918 million (as of June 30, 2026) | |||
| Cash and Equivalents | $530 million (as of June 30, 2026) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 10% in Q2 and 13% YTD compared to 2025. Growth was driven by volume increases (new products Zenrelia, Credelio Quattro, AdTab), favorable pricing, and foreign currency impacts.
- Profitability: Net income surged 391% in Q2 and 42% YTD. The effective tax rate dropped significantly to 3.3% in Q2 (from 55.4% in Q2 2025) due to jurisdictional mix and valuation allowance releases.
- Acquisition: Completed the acquisition of AHV International on April 30, 2026, for $243 million. This adds to the farm animal portfolio, particularly in cattle health.
- Restructuring: Incurred $25 million in asset impairment, restructuring, and special charges YTD 2026, including $15 million in non-cash shutdown costs for R&D facilities in Germany.
- Interest Expense: Increased 32% YTD to $116 million, primarily due to imputed interest on the liability for the sale of future revenue ($29 million YTD).
Guidance, Outlook, and Risks
- Product Pipeline: Launched Befrena (canine dermatitis) in Q2 2026. Credelio Quattro and Zenrelia continue to drive pet health volume. AHV integration is expected to have a modest revenue impact in 2026 with meaningful impact in 2027.
- Restructuring Plan: The 2025 Restructuring Plan targets $25–$30 million in pre-tax charges for 2026 (with $17 million already incurred) and expects savings of $25 million in 2026 and $60 million in 2027.
- Trade Environment: New U.S. tariffs under Section 301 and Section 232 are being monitored. Animal health products currently have significant carve-outs, but uncertainty remains regarding future applicability.
- Liquidity: The company maintains $530 million in cash and approximately $915 million in total unused borrowing capacity (Revolving Credit and Securitization Facilities). Management expects sufficient liquidity to meet obligations.
- Legal Proceedings: Several shareholder derivative and class action lawsuits remain pending or under appeal (e.g., Barpar, Hollin, Safron Capital). A settlement in principle was reached for the Kraus-Silfen and Spradlin matters involving a non-material payment.
Investor Verification Checklist
- Revenue Quality: Verify the sustainability of volume growth from new products (Zenrelia, Credelio Quattro) versus one-time channel inventory fluctuations.
- Debt Servicing: Monitor the impact of the "Liability for Sale of Future Revenue" ($315 million balance) on interest expense and cash flow, given the 18.3% effective interest rate on this liability.
- Restructuring Execution: Track the realization of the projected $60 million in annualized savings from the 2025 Restructuring Plan.
- Legal Exposure: Review the status of pending appeals in the Barpar securities class action and the Tevra antitrust matters.
- Acquisition Integration: Assess the timeline for AHV International to contribute meaningfully to revenue and margin expansion in 2027.